Eribulin mesylate was approved by the U.S. Food and Drug Administration on November 15, 2010, to treat patients with metastatic breast cancer. Structurally, eribulin is a fully synthetic macrocyclic ketone analogue of the marine sponge natural product halichondrin B. | |
Lizenzart: | Lizenzpflichtig |
Credit: | Science Photo Library / Degginger, Phil |
Bildgröße: | 9152 px × 7088 px |
Modell-Rechte: | nicht erforderlich |
Eigentums-Rechte: | nicht erforderlich |
Restrictions: | - |